Journal
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
Volume 65, Issue 8, Pages 223-229Publisher
WILEY
DOI: 10.1002/jlcr.3975
Keywords
5-HT2A receptor; automation; cGMP; fluorine-18; PET; radiochemistry
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases [P30DK058404]
- NIH Office of the Director [S10OD019963, S10OD023543, S10OD030436]
- NIH National Institute of Diabetes and Digestive and Kidney Diseases
- National Cancer Institute [P30CA068485]
- Vanderbilt University Medical Center
Ask authors/readers for more resources
In this study, a fully automated synthesis procedure for [F-18]MH.MZ radiotracer was developed using commercially available materials. The synthesis time was 100 min with a radiochemical yield of 7 +/- 0.9% (n = 3), and the radiochemical purity and molar activity met the relevant release criteria.
(R)-[F-18]MH.MZ ([F-18]MH.MZ) is a promising positron emission tomography (PET) radiotracer for in vivo study of the 5-HT2A receptor. To facilitate clinical trials, a fully automated radiosynthesis procedure for [F-18]MH.MZ was developed using commercially available materials on the iPhase Flexlab module. The overall synthesis time was 100 min with a radiochemical yield of 7 +/- 0.9% (n = 3). The radiochemical purity was greater than 99% for [F-18]MH.MZ with a molar activity of 361 +/- 57 GBq/mu mol (n = 3). The protocol described herein reliably provides [F-18]MH.MZ that meets all relevant release criteria for a GMP radiopharmaceutical.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
